Staar Surgical Company (STAA)
Summary
Deciphering Staar Surgical (STAA) International Revenue Trends
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STAAR Surgical Q2 Earnings Call Highlights
STAAR Surgical NASDAQ: STAA reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance.
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
STAAR Surgical Company (STAA) Q2 2026 Earnings Call Transcript
Staar Surgical Company Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 110 | $3,006.6 | $2,621.45 | -$385.15 | -12.81% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 35 | $617.05 | $828.1 | $211.05 | 34.2% |
| NA Nizar Araji National Bank Of Canada /FI/ | 6,483 | $190,146.39 | $156,953.43 | -$33,192.96 | -17.46% |
| BG Bart Gancher Intech Investment Management LLC | 49,107 | $1.44M | $1.19M | -$251,427.84 | -17.46% |
| JM John Malone Amundi | 15,951 | $298,283.7 | $400,689.12 | $102,405.42 | 34.33% |
Staar Surgical Company (STAA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Staar Surgical Company ever had a stock split?
Staar Surgical Company Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Warren Foust CEO | NASDAQ (NMS) Exchange | 852312305 CUSIP |
| US Country | 921 Employees | - Last Dividend | 18 May 1992 Last Split | 15 Jul 1983 IPO Date |
Overview
STAAR Surgical Company stands at the forefront of ophthalmic innovation, specialized in designing, developing, manufacturing, marketing, and selling implantable lenses for the eye, alongside companion delivery systems. Since its incorporation in 1982, STAAR Surgical has established itself as a pioneer in providing advanced solutions for visual disorders. Headquartered in Lake Forest, California, the company embarks on its mission to improve vision and enhance the quality of life for patients globally. By catering to health care providers such as ophthalmic surgeons, vision and surgical centers, hospitals, and government facilities, STAAR Surgical's reach extends widely across the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. Moreover, the company's global footprint expands through a network of representatives and independent distributors in regions such as China, Korea, India, France, Benelux, and Italy.
Products and Services
- Implantable Collamer Lens (ICL) Product Family: STAAR Surgical's flagship offering includes a variety of ICLs designed to correct visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia. The innovative lenses are implanted into the eye to provide a long-term solution that can eliminate or reduce the need for glasses or contact lenses. These lenses are favored for their biocompatibility, thanks to the unique Collamer material, and their ability to provide high-quality vision correction with minimal maintenance.
- Companion Delivery Systems: To enhance the effectiveness and safety of lens implantation, STAAR Surgical also provides specially designed delivery systems. These systems facilitate the precise and controlled delivery of the implantable lenses into the eye, ensuring a smooth surgical experience for both healthcare professionals and patients. The delivery systems are an integral part of the company’s portfolio, supporting the deployment of ICLs and contributing to their high success rate in vision correction.
